z-logo
Premium
Calcitonin gene‐related peptide potentiates nicotinic acetylcholine receptor‐operated slow Ca 2+ mobilization at mouse muscle endplates
Author(s) -
Salim Safaa Y,
Dezaki Katsuya,
Tsuneki Hiroshi,
AbdelZaher Ahmed O,
Kimura Ikuko
Publication year - 1998
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0702058
Subject(s) - calcitonin gene related peptide , medicine , endocrinology , acetylcholine , chemistry , long term potentiation , nicotinic agonist , acetylcholine receptor , nicotinic acetylcholine receptor , receptor , biology , neuropeptide
1 The involvement of calcitonin gene‐related peptide (CGRP) in the non‐contractile slow Ca 2+ mobilization induced by prolonged nicotinic stimulation was investigated by measurement of [Ca 2+ ] i levels in mouse single muscle cells (flexor digitorum brevis; FDB) loaded with a Ca 2+ indicator fluo‐3 using confocal laser scanning microscopy. 2 CGRP (3–30 n M ) potentiated acetylcholine (ACh, 1 μ M )‐elicited slow Ca 2+ mobilization in a concentration‐dependent manner. 3 The potentiation by CGRP of the slow Ca 2+ component was greatly depressed by a competitive nicotinic antagonist (+)‐tubocurarine (5 μ M ). The Ca 2+ channel blocker nitrendipine (1 μ M ) affected neither ACh responses nor the CGRP potentiation. 4 The slow Ca 2+ component was completely abolished by reducing [Ca 2+ ] 0 from 2.5 to 0.25 m M whereas the fast component was not affected. The CGRP‐induced potentiation of slow Ca 2+ signal was also depressed by decreasing [Ca 2+ ] 0 . 5 Isoproterenol (30 μ M ) and 8‐bromo‐adenosine 3′,5′‐cyclic monophosphate (1 m M ) potentiated the ACh‐elicited slow Ca 2+ response. The potentiation by CGRP of the slow Ca 2+ component was completely abolished by a protein kinase‐A inhibitor H‐89 (1 μ M ). 6 These findings indicate that CGRP potentiates the nicotinic ACh receptor‐operated slow Ca 2+ signal via the activation of protein kinase‐A system at the skeletal muscle endplates.British Journal of Pharmacology (1998) 125 , 277–282; doi: 10.1038/sj.bjp.0702058

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom